The benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to be worth US$ 33,031.10 million in 2024. The market is expected to grow at a steady rate over the period from 2024 to 2034, with a CAGR of 3.6%. By the end of the forecast period, the market value is predicted to hit US$ 47,045.80 million.
Attributes | Details |
---|---|
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Value for 2024 | US$ 33,031.10 million |
Projected Market Value for 2034 | US$ 47,045.80 million |
Value-based CAGR of Market for 2024 to 2034 | 3.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Drugs continue to be the preferred treatment type for BPH. Institutional sales top the distribution channel segment.
For 2024, drugs are expected to account for 65.2% of the market share by treatment type. Some of the key drivers for the increasing use of drugs in BPH treatment are:
Attributes | Details |
---|---|
Top Treatment Type | Drugs |
Market Share (2024) | 65.2% |
Institutional sales are anticipated to account for 64.7% of the market share in 2024. Some of the key drivers for the progress of institutional sales include:
Attributes | Details |
---|---|
Top Distribution Channel | Institutional Sales |
Market Share (2024) | 64.7% |
The increasing geriatric population is contributing to the market’s acceleration in North America. The presence of a wide variety of treatments is also propelling the benign prostatic hyperplasia (BPH) prostate treatment industry in North America.
Advancement of research institutions is lending a helping hand to the progress of the market in the region. The focus on the technological development of healthcare companies in the region is making sure BPH treatment keeps up with the times in Europe.
Countries | CAGR |
---|---|
United States | 4.0% |
Canada | 3.1% |
United Kingdom | 3.7% |
France | 3.3% |
Italy | 3.5% |
The market is set to register a CAGR of 4.0% in the United States for the forecast period. The key drivers for growth are:
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in Canada is tipped to be 3.1% over the forecast period. Some of the key factors driving the growth are:
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in the United Kingdom is tipped to be 3.7% over the forecast period. Some of the key factors driving the growth are:
The market is expected to register a CAGR of 3.3% in France for the forecast period. Some of the key trends include:
The market is expected to register a CAGR of 3.5% in Italy over the forecast period. Some of the key trends include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The benign prostatic hyperplasia (BPH) prostate treatment market is competitive, though a few companies are prominent in the market. One of the well-established companies in the market is Pfizer Inc., who are concentrated on expansion through its alpha-blockers range.
Other players in the market are implementing strategies such as acquisitions and mergers to get a competitive edge. Research and development are also given importance by these market players.
Recent Developments in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
The benign prostatic hyperplasia (BPH) prostate treatment market size is expected to be worth US$ 33,031.10 million in 2024.
The benign prostatic hyperplasia (BPH) prostate treatment market is estimated to get as big as US$ 47,045.80 million in 2034.
The CAGR of the benign prostatic hyperplasia (BPH) prostate treatment market during the 2024 to 2034 period in the United States is estimated to be 4.0%.
The benign prostatic hyperplasia (BPH) prostate treatment market can be divided into the following segments: treatment type and distribution channel.
The benign prostatic hyperplasia (BPH) prostate treatment market is expected to grow at a CAGR of 3.6% over the period from 2024 to 2034.
Pfizer Inc., NxThera Inc., NeoTract Inc., and Sanofi S.A. are some of the key companies in the benign prostatic hyperplasia (BPH) prostate treatment Market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2024 to 2034 5.3.1. BPH Drugs 5.3.1.1. Alpha Blockers 5.3.1.2. 5-Aplha Reductase Inhibitors 5.3.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 5.3.1.4. Muscarinic Receptor Antagonist (MRA) 5.3.1.5. Combination Drug 5.3.2. BPH Devices 5.3.2.1. Prostatic Stents 5.3.2.2. Suture Base Implant Systems 5.3.2.3. Transurethral RF Thermal Therapy Devices 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Institutional Sales 6.3.1.1. Hospitals 6.3.1.2. Ambulatory Surgical Centres 6.3.1.3. Specialty Clinics 6.3.2. Retail Sales 6.3.2.1. Retail Pharmacies 6.3.2.2. Drug Stores 6.3.3. Online Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Treatment Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Treatment Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Treatment Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Market Share Analysis, 2023 15.1.1.1. By Treatment Type 15.1.1.2. By Distribution Channel 15.2. Canada 15.2.1. Market Share Analysis, 2023 15.2.1.1. By Treatment Type 15.2.1.2. By Distribution Channel 15.3. Brazil 15.3.1. Market Share Analysis, 2023 15.3.1.1. By Treatment Type 15.3.1.2. By Distribution Channel 15.4. Mexico 15.4.1. Market Share Analysis, 2023 15.4.1.1. By Treatment Type 15.4.1.2. By Distribution Channel 15.5. Germany 15.5.1. Market Share Analysis, 2023 15.5.1.1. By Treatment Type 15.5.1.2. By Distribution Channel 15.6. UK 15.6.1. Market Share Analysis, 2023 15.6.1.1. By Treatment Type 15.6.1.2. By Distribution Channel 15.7. France 15.7.1. Market Share Analysis, 2023 15.7.1.1. By Treatment Type 15.7.1.2. By Distribution Channel 15.8. Spain 15.8.1. Market Share Analysis, 2023 15.8.1.1. By Treatment Type 15.8.1.2. By Distribution Channel 15.9. Italy 15.9.1. Market Share Analysis, 2023 15.9.1.1. By Treatment Type 15.9.1.2. By Distribution Channel 15.10. Poland 15.10.1. Market Share Analysis, 2023 15.10.1.1. By Treatment Type 15.10.1.2. By Distribution Channel 15.11. Russia 15.11.1. Market Share Analysis, 2023 15.11.1.1. By Treatment Type 15.11.1.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Market Share Analysis, 2023 15.12.1.1. By Treatment Type 15.12.1.2. By Distribution Channel 15.13. Romania 15.13.1. Market Share Analysis, 2023 15.13.1.1. By Treatment Type 15.13.1.2. By Distribution Channel 15.14. India 15.14.1. Market Share Analysis, 2023 15.14.1.1. By Treatment Type 15.14.1.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Market Share Analysis, 2023 15.15.1.1. By Treatment Type 15.15.1.2. By Distribution Channel 15.16. Australia 15.16.1. Market Share Analysis, 2023 15.16.1.1. By Treatment Type 15.16.1.2. By Distribution Channel 15.17. New Zealand 15.17.1. Market Share Analysis, 2023 15.17.1.1. By Treatment Type 15.17.1.2. By Distribution Channel 15.18. China 15.18.1. Market Share Analysis, 2023 15.18.1.1. By Treatment Type 15.18.1.2. By Distribution Channel 15.19. Japan 15.19.1. Market Share Analysis, 2023 15.19.1.1. By Treatment Type 15.19.1.2. By Distribution Channel 15.20. South Korea 15.20.1. Market Share Analysis, 2023 15.20.1.1. By Treatment Type 15.20.1.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Market Share Analysis, 2023 15.21.1.1. By Treatment Type 15.21.1.2. By Distribution Channel 15.22. South Africa 15.22.1. Market Share Analysis, 2023 15.22.1.1. By Treatment Type 15.22.1.2. By Distribution Channel 15.23. Israel 15.23.1. Market Share Analysis, 2023 15.23.1.1. By Treatment Type 15.23.1.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Pfizer Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. NxThera Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. NeoTract Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Sanofi S.A 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. GlaxoSmithKline Plc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Allergan Plc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Teva Pharmaceutical Industries Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Mylan N.V. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Eli Lily & Company 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Cardinal Health Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports